JP2003508028A - 腫瘍治療のための組成物と方法 - Google Patents

腫瘍治療のための組成物と方法

Info

Publication number
JP2003508028A
JP2003508028A JP2001513995A JP2001513995A JP2003508028A JP 2003508028 A JP2003508028 A JP 2003508028A JP 2001513995 A JP2001513995 A JP 2001513995A JP 2001513995 A JP2001513995 A JP 2001513995A JP 2003508028 A JP2003508028 A JP 2003508028A
Authority
JP
Japan
Prior art keywords
adam8
antibody
polypeptide
expression
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001513995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003508028A5 (enExample
Inventor
ボーダリー，サラ，シー．
フィッシャー，カレン，エル．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2003508028A publication Critical patent/JP2003508028A/ja
Publication of JP2003508028A5 publication Critical patent/JP2003508028A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2001513995A 1999-07-28 2000-07-27 腫瘍治療のための組成物と方法 Withdrawn JP2003508028A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14621799P 1999-07-28 1999-07-28
US60/146,217 1999-07-28
PCT/US2000/020731 WO2001009189A2 (en) 1999-07-28 2000-07-27 Compositions and methods for the treatment of tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011231764A Division JP5897300B2 (ja) 1999-07-28 2011-10-21 腫瘍治療のための組成物と方法

Publications (2)

Publication Number Publication Date
JP2003508028A true JP2003508028A (ja) 2003-03-04
JP2003508028A5 JP2003508028A5 (enExample) 2007-10-04

Family

ID=22516336

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2001513995A Withdrawn JP2003508028A (ja) 1999-07-28 2000-07-27 腫瘍治療のための組成物と方法
JP2011231764A Expired - Lifetime JP5897300B2 (ja) 1999-07-28 2011-10-21 腫瘍治療のための組成物と方法
JP2014040627A Pending JP2014144959A (ja) 1999-07-28 2014-03-03 腫瘍治療のための組成物と方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011231764A Expired - Lifetime JP5897300B2 (ja) 1999-07-28 2011-10-21 腫瘍治療のための組成物と方法
JP2014040627A Pending JP2014144959A (ja) 1999-07-28 2014-03-03 腫瘍治療のための組成物と方法

Country Status (9)

Country Link
US (2) US7226596B2 (enExample)
EP (1) EP1204682B1 (enExample)
JP (3) JP2003508028A (enExample)
AT (1) ATE488529T1 (enExample)
AU (1) AU776600B2 (enExample)
CA (1) CA2378182C (enExample)
DE (1) DE60045247D1 (enExample)
ES (1) ES2355055T3 (enExample)
WO (1) WO2001009189A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008525041A (ja) * 2004-12-22 2008-07-17 ジェネンテック・インコーポレーテッド 可溶性多膜貫通型タンパク質の産生方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2378182C (en) * 1999-07-28 2014-09-23 Genentech, Inc. Compositions and methods for the treatment of tumors
US7157567B2 (en) 2002-02-20 2007-01-02 Astellas Pharma, Inc. Polypeptide
CN101586155A (zh) * 2002-09-30 2009-11-25 肿瘤疗法科学股份有限公司 非小细胞肺癌的诊断方法
US20080014594A1 (en) * 2003-01-31 2008-01-17 Kevin Hestir Lung-Expressed Polypeptides
EP1730533A1 (en) * 2004-03-24 2006-12-13 Oncotherapy Science, Inc. Adam8 as tumor marker and therapeutic target for non-small cell lung cancer
ES2318575T3 (es) * 2004-11-10 2009-05-01 Novartis Vaccines And Diagnostics, Inc. Interferon beta desamidado.
FR2879462B1 (fr) * 2004-12-21 2008-12-26 Sod Conseils Rech Applic Utilisation de toxine botulique pour une insensibilisation locale prolongee
US20060242012A1 (en) * 2005-04-22 2006-10-26 Sumit Agarwal Determining or scoring properties to solicit to join ad network using advertiser or aggregated advertiser interest
AU2007336243B2 (en) 2006-12-19 2012-07-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
GB2453589A (en) 2007-10-12 2009-04-15 King S College London Protease inhibition
MX2010005811A (es) * 2007-11-27 2010-06-09 Veridex Llc Enumeracion automatica y caracterizacion de las celulas del melanoma circulantes en la sangre.
WO2010081173A2 (en) * 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
WO2014186364A2 (en) * 2013-05-13 2014-11-20 Tufts University Methods and compositions for prognosis, diagnosis and treatment of adam8-expressing cancer
TW201613622A (en) * 2014-10-14 2016-04-16 Bionet Corp Composition for skincare and pharmaceutical composition and preparation method thereof
TW201613621A (en) * 2014-10-14 2016-04-16 Bionet Corp Composition for promoting growth of dermal papilla cells, pharmaceutical composition, and preparation method thereof
JP2018130113A (ja) * 2017-02-15 2018-08-23 国立大学法人 東京大学 慢性骨髄性白血病（ｃｍｌ）の検査方法及び検査用キット、チロシンキナーゼ阻害剤（ｔｋｉ）耐性ｃｍｌの単離方法、並びにｃｍｌにおけるｔｋｉ耐性の低減剤及びそのスクリーニング方法
AU2020283906A1 (en) * 2019-05-31 2022-01-20 Trustees Of Tufts College Anti-ADAM8 antibodies and uses of the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04187084A (ja) * 1990-11-22 1992-07-03 Otsuka Pharmaceut Co Ltd 単球表面に発現する抗原及び該抗原に対するモノクローナル抗体
WO1998051706A1 (en) * 1997-05-13 1998-11-19 Incyte Pharmaceuticals, Inc. Tumor-associated antigen
WO1998057665A2 (en) * 1997-03-18 1998-12-23 Oxford Biomedica (Uk) Limited The use of mononuclear phagocytes in in vivo imaging of hypoxic/ischaemic tissue

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0822186T3 (da) * 1994-01-20 2000-06-26 British Biotech Pharm L-tert-leucin-2-pyridylamid
GB9608130D0 (en) 1996-04-19 1996-06-26 Univ Sheffield Adam proteins and uses thereof
ATE244579T1 (de) * 1997-01-22 2003-07-15 Univ Texas Verfahren und zusammensetzungen des gewebefaktors zur koagulation und behandlung von tumoren
GB2339200B (en) * 1998-06-06 2001-09-12 Genostic Pharma Ltd Genostics
WO2000040749A2 (en) * 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
US20010034023A1 (en) * 1999-04-26 2001-10-25 Stanton Vincent P. Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
CA2378182C (en) * 1999-07-28 2014-09-23 Genentech, Inc. Compositions and methods for the treatment of tumors
EP1259595B1 (en) * 2000-02-25 2007-04-04 Immunex Corporation Integrin antagonists
ES2264440T3 (es) * 2000-03-24 2007-01-01 Micromet Ag Amplificacion de mrna.
US6458552B1 (en) * 2000-06-06 2002-10-01 Ortho-Mcneil Pharmaceutical, Inc. Metalloprotease peptide substrates and methods
AU2002213005A1 (en) * 2000-10-02 2002-04-15 Board Of Regents, The University Of Texas System Method of detection and interpretation of mutations through expression or function tests of haploid genes
AU2002230997A1 (en) * 2000-12-15 2002-06-24 Genetics Institute, Llc Methods and compositions for diagnosing and treating rheumatoid arthritis
WO2002085285A2 (en) * 2001-04-18 2002-10-31 Wyeth Methods and reagents for regulating bone and cartilage formation
US20030138792A1 (en) * 2001-05-31 2003-07-24 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer
AU2002318944A1 (en) * 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
US20030148334A1 (en) * 2001-10-12 2003-08-07 Zairen Sun Differentially-expressed genes and polypeptides in angiogenesis
EP1527196A4 (en) * 2002-03-01 2007-03-14 Childrens Hosp Medical Center TREATMENT OF ASTHMA AND ALLERGIES
US20040018522A1 (en) * 2002-05-09 2004-01-29 Brigham And Women's Hospital, Inc. Identification of dysregulated genes in patients with multiple sclerosis
US20050003390A1 (en) * 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
JP2004041121A (ja) * 2002-07-12 2004-02-12 Hitachi Ltd アレルギー解析方法及びシステム
US7482117B2 (en) * 2002-12-20 2009-01-27 Celera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
EP1613269B1 (en) * 2003-04-04 2015-02-25 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
US20050009067A1 (en) * 2003-05-19 2005-01-13 Craig Logsdon Expression profile of pancreatic cancer
US20050059101A1 (en) * 2003-09-10 2005-03-17 Gordon Ringold Bivalent targeting of cell surfaces

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04187084A (ja) * 1990-11-22 1992-07-03 Otsuka Pharmaceut Co Ltd 単球表面に発現する抗原及び該抗原に対するモノクローナル抗体
WO1998057665A2 (en) * 1997-03-18 1998-12-23 Oxford Biomedica (Uk) Limited The use of mononuclear phagocytes in in vivo imaging of hypoxic/ischaemic tissue
WO1998051706A1 (en) * 1997-05-13 1998-11-19 Incyte Pharmaceuticals, Inc. Tumor-associated antigen

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008525041A (ja) * 2004-12-22 2008-07-17 ジェネンテック・インコーポレーテッド 可溶性多膜貫通型タンパク質の産生方法
US8323902B2 (en) 2004-12-22 2012-12-04 Genentech, Inc. Methods for producing soluble membrane-spanning proteins

Also Published As

Publication number Publication date
WO2001009189A3 (en) 2001-06-14
DE60045247D1 (de) 2010-12-30
ATE488529T1 (de) 2010-12-15
US7226596B2 (en) 2007-06-05
CA2378182C (en) 2014-09-23
AU776600B2 (en) 2004-09-16
ES2355055T3 (es) 2011-03-22
US20080175842A1 (en) 2008-07-24
WO2001009189A2 (en) 2001-02-08
US20030113764A1 (en) 2003-06-19
EP1204682B1 (en) 2010-11-17
EP1204682A2 (en) 2002-05-15
JP2012068254A (ja) 2012-04-05
JP5897300B2 (ja) 2016-03-30
CA2378182A1 (en) 2001-02-08
JP2014144959A (ja) 2014-08-14
AU6391300A (en) 2001-02-19

Similar Documents

Publication Publication Date Title
JP5897300B2 (ja) 腫瘍治療のための組成物と方法
JP5701624B2 (ja) 新規なｓｔｒａ６ポリペプチド
EP1607402B1 (en) Method for the diagnosis of tumour
JP4252501B2 (ja) 腫瘍の治療のための組成物と方法
JP2009000114A (ja) 腫瘍治療のための組成物及び方法
US20050176104A1 (en) Compositions and methods for the treatment of tumor
JP2005531491A (ja) 癌の治療のための組成物と方法
JP2003519491A5 (enExample)
JP2006519774A (ja) 癌の治療のための組成物と方法
JP2003524390A (ja) 腫瘍治療のための組成物及び方法
JP2003524380A (ja) 腫瘍治療のための組成物及び方法
JP3659405B2 (ja) Ｓｈ２ドメイン含有ペプチド
JP2002534987A (ja) 腫瘍の治療のための組成物と方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070727

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101004

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101012

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101203

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111021

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20111028

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20111122